C1 Esterase Inhibitor Subcutaneous (Human)

Introduction Overview

Generic Name

c1 esterase inhibitor subcutaneous (human)

Brand Name

Haegarda

Dosage Form

Injectable solution for subcutaneous injection

Drug Class

Hereditary angioedema agents

Pharmacokinetics

Absorption:
Haegarda is administered subcutaneously, allowing for gradual absorption into the systemic circulation. Subcutaneous injection bypasses first-pass metabolism and provides a steady release of the c1 esterase inhibitor protein into plasma. Clinical pharmacokinetic studies demonstrate that peak plasma concentrations of functional C1 esterase inhibitor activity are typically reached several hours post-dose, reflecting slow absorption kinetics compared to intravenous administration. The absorption profile supports twice-weekly dosing to maintain therapeutic plasma levels above the threshold required to prevent angioedema attacks.

Distribution:
Following absorption, Haegarda distributes primarily within the intravascular and interstitial fluid compartments. The recombinant human C1 esterase inhibitor protein is a large glycoprotein with limited tissue penetration, restricting distribution mainly to vascular and extracellular spaces. Volume of distribution approximates plasma volume, consistent with its plasma protein nature. Binding to endogenous targets such as activated complement components and proteases influences distribution dynamics. The distribution characteristics ensure adequate availability at sites prone to swelling and vascular permeability changes.

Metabolism:
Haegarda is a biologic protein that undergoes catabolism via proteolytic enzymes throughout the reticuloendothelial system, like endogenous plasma proteins. The injected recombinant C1 esterase inhibitor does not undergo classical hepatic metabolism but instead is broken down into amino acids and small peptides after exerting its pharmacologic actions or clearance. Its half-life is influenced by receptor-mediated endocytosis and protease degradation. There is no evidence of involvement of cytochrome P450 enzymes or other phase I/II metabolic pathways.

Elimination:
Elimination of Haegarda occurs primarily via proteolysis and clearance of protein fragments through normal protein catabolic pathways. Urinary excretion of intact protein is negligible due to its large molecular size. The elimination half-life supports dosing intervals of every 3 to 4 days for prophylaxis. No significant accumulation is observed with repeated dosing. Renal or hepatic impairment does not markedly affect elimination, given the protein's degradation via systemic lysosomal pathways.

Dosage Forms

Available Dosage Forms:
Haegarda is supplied as a sterile, preservative-free powder in single-dose vials, which must be reconstituted with sterile water for injection prior to administration.
Specific dosage strengths include:
- Vials containing 500 International Units (IU) of c1 esterase inhibitor protein per vial.

Dosages for Adults and Adolescents:
Haegarda is indicated for routine prophylaxis of hereditary angioedema attacks in patients aged 6 years and older. The recommended dosage is 60 IU per kg body weight administered subcutaneously twice weekly, approximately every 3 or 4 days.
The injection is given subcutaneously, and patients or caregivers must be trained to perform self-administration.

Specific Patient Populations:
Pediatric patients aged 6 years and older can use Haegarda at the same weight-based dosing regimen as adults.
There is limited data in patients younger than 6 years; clinical use in this group should be carefully evaluated.
Haegarda should not be used to treat acute HAE attacks, only for prophylaxis.
No dose adjustments are specifically recommended for renal or hepatic impairment.

Storage Considerations:
Unopened vials should be stored refrigerated or at cool room temperature and protected from light.
After reconstitution, Haegarda should be used immediately or stored at room temperature and administered within 8 hours.
The product is preservative-free, and any vial once punctured must be used immediately or discarded.

Mechanism Of Action

Haegarda is a recombinant, human plasma-derived form of C1 esterase inhibitor (C1-INH), a vital regulatory protein. In hereditary angioedema (HAE), patients lack sufficient functional C1-INH, leading to unchecked activation of the complement and contact systems. This results in excessive production of bradykinin, a potent vasodilator that increases vascular permeability, causing recurrent, localized swelling.

Upon subcutaneous administration, Haegarda replenishes deficient or dysfunctional C1-INH in plasma. The protein acts primarily by inhibiting activated C1r and C1s components of the classical complement pathway, preventing complement activation and downstream inflammatory cascades. Additionally, it regulates the kallikrein-kinin system by inhibiting plasma kallikrein and factor XIIa, thereby reducing bradykinin generation.

By restoring functional C1-INH levels, Haegarda decreases endothelial permeability and vascular leakage, reducing frequency and severity of angioedema episodes. Unlike acute treatments, it serves as prophylaxis by maintaining steady plasma levels that continuously inhibit protease activation, preventing the formation of bradykinin before attack onset.

Comparatively, other HAE therapies either target bradykinin directly (e.g., icatibant) or inhibit kallikrein enzymatic activity (e.g., lanadelumab). Haegarda’s mode of action as a replacement therapy addresses upstream regulatory deficiencies, making it a physiologically based prophylactic agent. Clinical trials have demonstrated significant reductions in attack rates with its use in both pediatric and adult populations, confirming the clinical relevance of its molecular mechanism.

Pharmacological Actions

Replacement of deficient or dysfunctional C1 esterase inhibitor protein in hereditary angioedema patients
Inhibition of the classical complement pathway activation by blocking activated C1r and C1s enzymes
Regulation of the kallikrein-kinin system, decreasing plasma kallikrein and factor XIIa activity
Reduction of bradykinin production, a key mediator of vascular permeability and angioedema
Prevention of recurrent angioedema attacks through maintenance of steady plasma enzyme inhibition
Anti-edematous effect by stabilizing endothelial barrier function and decreasing vascular leakage
Immunomodulatory impacts by controlling complement activation and inflammatory cascades
Provides prophylactic activity rather than acute symptom relief
Derived from purified human plasma protein, thereby mimicking physiologic regulatory processes
Facilitates self-administration due to subcutaneous formulation enhancing ease of use
Minimal immunogenicity reported due to human origin and biochemical similarity to endogenous protein
No direct influence on other coagulation pathways outside of complement and contact systems
Does not interfere with cytochrome P450 metabolism or traditional drug-metabolizing enzymes
Supports long-term management of hereditary angioedema by preventing debilitating attacks
Demonstrates favorable safety profile consistent with endogenous plasma protein replacement

Therapeutic Or Clinical Uses

Routine prophylaxis to prevent hereditary angioedema (HAE) attacks in patients aged 6 years and older
Reduction in frequency, severity, and duration of angioedema episodes in hereditary angioedema
Maintenance therapy for patients with confirmed C1 esterase inhibitor deficiency or dysfunction
Prevention of potentially life-threatening airway swelling associated with HAE
Adjunctive therapy to improve quality of life and reduce hospitalizations related to angioedema
Suitable for self-administration after proper training, facilitating outpatient management
Alternative for patients intolerant or unresponsive to other prophylactic agents
Prophylaxis in both adult and pediatric populations with hereditary angioedema
Not indicated for treatment of acute HAE attacks; reserved for prevention only
Useful in patients with hereditary angioedema types I and II caused by C1-INH deficiency
May reduce the need for acute HAE therapies and emergency interventions
Supports consistent therapeutic coverage with twice-weekly subcutaneous injections
Safe for routine use under medical supervision with appropriate monitoring
Applied in clinical contexts where hereditary angioedema causes recurrent swelling episodes
Implements biochemical replacement strategy to address underlying cause of HAE

Side Or Adverse Effects

Unusual or unpleasant taste in the mouth following injection
Headache and dizziness commonly reported post-administration
Nausea and vomiting may occur transiently in some patients
Injection site reactions including pain, bruising, itching, swelling, bleeding, warmth, or formation of a hard lump
Upper respiratory symptoms such as stuffy nose and sore throat
Cutaneous rash potentially associated with hypersensitivity
Fever observed in rare cases after dosing
Signs of allergic reactions including urticaria, chest tightness, fast heartbeat, light-headedness, wheezing, or swelling of face, lips, tongue, or throat
Potential for severe hypersensitivity or anaphylaxis necessitating immediate medical attention
Rare reports of thromboembolic events, especially in patients with prothrombotic risk factors
Occurrence of numbness or weakness on one side of the body requiring urgent evaluation
Pain, swelling, redness or warmth in limbs indicating possible thrombosis
Severe headache, confusion, visual disturbances, speech or balance problems as neurological warning signs
Chest pain during deep breaths meriting prompt clinical investigation
Tachycardia or fast heart rate as potential cardiovascular adverse effect

Precautions

Do not use if there is known life-threatening hypersensitivity to c1 esterase inhibitor or excipients
Inform your healthcare provider of any history of stroke or thromboembolic events
Caution advised in patients with cardiac disease or cardiovascular risk factors
Use care if an indwelling catheter is present due to increased infection or thrombosis risk
Pregnancy and breastfeeding safety has not been firmly established; consult physician before use
Haegarda is derived from human plasma; although screened and treated, a risk of viral transmission remains
Follow strict aseptic technique during reconstitution and injection to prevent infections
Store product as directed, avoiding freezing and exposure to light to maintain stability
Discard any vial after single use; do not reuse to avoid contamination
Patients should be trained in proper injection technique and disposal of needles to avoid injury
Monitor for early signs of hypersensitivity during initial and subsequent administrations
Inform healthcare provider about all medications to assess potential interactions
Missed doses should be managed per physician’s advice to maintain adequate prophylactic protection
Do not use Haegarda to treat acute HAE attacks; specific acute therapies should be initiated promptly
Maintain emergency access to acute HAE treatments despite prophylactic use of Haegarda

Warnings

Contraindicated in patients with known life-threatening immediate hypersensitivity reactions to Haegarda
Anaphylaxis or severe allergic reactions may occur; emergency medical equipment should be available during administration
Not intended for treatment of acute hereditary angioedema attacks; inappropriate use can delay effective acute therapy
Use caution in patients with risk factors for thrombotic events, as rare thromboembolism has been reported
Potential for transmission of infectious agents despite plasma-derived product screening and processing
Injection site reactions can be severe and require medical evaluation if persistent or worsening
Discontinue if signs of allergic reaction occur and seek emergency care immediately
Patients experiencing neurological symptoms such as sudden numbness, weakness, or severe headache must seek urgent care
Monitor for cardiovascular symptoms including chest pain or tachycardia during treatment course
Ensure correct dosing and administration schedule strictly adhered to prevent suboptimal prophylaxis
Avoid freezing product during storage as it may reduce efficacy
Do not share injection devices or vials between patients to prevent cross-contamination
Educate patients to recognize symptoms of hypersensitivity and thrombosis
Use in pregnancy only if clearly needed and after benefit-risk assessment
Keep out of reach of children to prevent accidental exposure or misuse

Contraindication

Known life-threatening allergic reaction or anaphylaxis to c1 esterase inhibitor or any component of Haegarda
Hypersensitivity to any ingredient used in the formulation
Not to be used for acute treatment of hereditary angioedema attacks, only for prophylaxis
Contraindicated in patients with history of immediate hypersensitivity reactions to human plasma-derived products
Do not use in patients with known hypersensitivity to product diluents or reconstitution agents
Not recommended for patients younger than 6 years due to lack of safety data
Contraindicated in patients with active thrombosis or thromboembolic disorders without physician oversight
Use contraindicated in patients without hereditary angioedema due to C1 esterase inhibitor deficiency or dysfunction
Avoid use if active infection at injection site is present
Contraindications also include patients with known hypersensitivity to components used for viral reduction steps
Use with caution or avoid in patients with immunoglobulin A deficiency with antibodies against IgA
Contraindicated in patients who have developed neutralizing antibodies to C1 esterase inhibitor resulting in reduced efficacy
Patients with hypersensitivity reactions to recombinant or plasma-derived C1-INH should not receive this treatment
Contraindication extends to inappropriate off-label uses unrelated to hereditary angioedema prophylaxis
Discontinue if severe hypersensitivity manifestations develop

Drug Interactions

Potential interactions with testosterone therapy, which may influence hereditary angioedema disease course
Possible interaction with hormonal contraceptives or birth control pills affecting treatment outcomes
No known significant interaction with cytochrome P450 metabolized drugs due to protein nature
No major interactions reported with over-the-counter medications, vitamins or herbal supplements
Monitor for additive risk of thrombosis when combined with other prothrombotic agents
Concurrent use with other plasma-derived or recombinant C1 esterase inhibitors requires medical supervision
Interactions with anticoagulants or antiplatelet agents should be closely monitored due to bleeding concerns
Immunomodulatory drugs may theoretically affect efficacy but no direct interaction documented
Avoid simultaneous intravenous infusion with other protein therapeutics unless clinically indicated
No known interactions with vaccines, but immunization scheduling should be coordinated
Concurrent use with angiotensin-converting enzyme inhibitors (ACE inhibitors) that increase bradykinin should be cautiously assessed
Potential interactions with drugs affecting complement system function warrant careful monitoring
Patients should inform all healthcare providers about Haegarda therapy to avoid inadvertent interactions
Consult pharmacist or physician prior to starting new medications to evaluate interaction potential
Report any unexpected side effects or reduced efficacy that may suggest drug interaction

Preparations Of The Drug

Sterile lyophilized powder in single-dose vials containing 500 International Units (IU) of human plasma-derived c1 esterase inhibitor
Preservative-free formulation requiring reconstitution with sterile water for injection prior to administration
Packaged with sterile water vials for reconstitution included in the kit
Supplied in boxes containing multiple single-dose vials for patient dosing convenience
Instructions for use provided to guide proper preparation and subcutaneous injection technique
Storage recommendation to refrigerate or keep at cool room temperature protected from light
Once reconstituted, the product must be used immediately or within 8 hours if kept at room temperature
Single-use vials; any unused portion must be discarded to prevent contamination
Syringes and needles for injection supplied separately; healthcare professionals train patients for self-administration
Packaged for subcutaneous administration targeting easy home use after initial medical supervision
Includes safety data sheets and patient information leaflets outlining proper usage and disposal
Manufactured under strict plasma donor screening and viral inactivation procedures to ensure safety
Lot numbers and expiration dates printed on vials to ensure product traceability and quality control
Biosimilar reference product equivalent: Cinryze, used for similar therapeutic indications
No preservatives included, thereby necessitating strict aseptic handling during preparation